Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Cách tiếp cận phổ biến nhất được sử dụng, tuy nhiên, là xác định mà mắt là mắt chi phối và sửa chữa mắt cho khoảng cách xem thường được sử dụng nhất (11), mà nói chung là được coi là khoảng cách xa. | N o Table 1 Visual and Refractive Outcomes Marcel Dekker Inc. 270 Madison Avenue New York New York 10016 Phakic IOL No. of eyes Follow-up months ES D preop type Authors Artisan Fechner 10 1998 67 78.1 12 to 120 6 to 18 9.98 2.6 Artisan Hoang-Xuan and Malecaze 2001 unpublished data 9 12 4.40 to 18.12 6.61 0.35 STAAR Rosen 11 1998 9 3 2.25 to 5.62 STAAR Davidorf 12 1999 24 8.4 1 to 18 3.75 to 10.50 6.51 2.08 STAAR Pesando 13 1999 15 12 6 to 18 4.75 to 11.75 7.77 2.08 STAAR Sanders 14 1999 10 6 2.50 to 10.88 6.23 ES D postop Refractive outcome D 0.50 eyes Refractive outcome D 1.00 eyes Uncorrected VA postop 20 40 orbetter eyes Uncorrected VA postop 20 20 or better eyes -5 to 3.5 0.07 2.03 -0.75 to 0.75 66.7 100 67 11 -0.08 0.71 -0.12 to 0.50 88.8 89 44 -3.88 to 1.25 58 79 63 8 -0.39 1.29 -1.00 to 1.50 69.25 92.3 46.15 0 0.02 0.64 -0.50 to 1.50 0.20 0.61 80 90 100 70 Hoang-Xuan and Malecaze Copyright Marcel Dekker Inc. All rights reserved. Hyperopic Phakic Intraocular Lenses 127 Table 2 Safety of Hyperopic Phakic Intraocular Lenses Phakic IOL type Authors Loss of BSCVA eyes Unchanged BSCVA eyes Gain of BSCVA eyes Complications Artisan Artisan Fechner 10 1998 Hoang-Xuan and 22.2 1 line 0 22.2 1 line One glaucoma and corneal edema in two eyes of same patient None STAAR STAAR Malecaze 2001 unpublished data Rosen 11 1998 Davidorf 12 1999 55.5 2 lines 25 1 line 44.4 33 22.2 1 line 22.2 2 lines 29 1 line Three pupillary STAAR Pesando 13 1999 4 2 lines 7.69 76.92 4 2 lines 4 2 lines 15.38 block glaucomas Two pupillary STAAR Sanders 14 1999 0 2 3 lines block glaucomas One lens opacity None 2. STAAR Collamer Phakic IOL Four studies on hyperopic correction using the STAAR Collamer phakic lens have been published 11-14 . These studies included 9 24 15 and 10 hyperopes respectively the latter study 14 being a phase I clinical trial sponsored by the U.S. Food and Drug Administration. In total 58 patients underwent STAAR Collamer phakic IOL implantation. Cumulative data show that .
